Has the capacity to offer absolute protection for more than eight million samples
LabConnect, a US-based provider of central laboratory services to biopharmaceutical, medical device and contract research organisations, has built a new biorepository facility with storage capacity for more than eight million samples.
LabConnect’s new, 5,000ft2 (465m2) biorepository in Johnson City, Tennessee features space for ambient, refrigerated, cold (-20ºC) and ultra-low temperature (-70ºC to -80ºC) storage as well as liquid nitrogen vapour phase storage (-190ºC).
'Proper sample management is essential to both today’s and tomorrow’s clinical trials,' said Eric Hayashi, LabConnect's President and CEO.
'Researchers depend on the integrity and availability of their stored biospecimens to retest them to verify trends or unexpected results, or for later retrieval to support specific biomarker research.'
LabConnect ensures the integrity of samples as well as business continuity with fully validated and mapped backup freezers and generators, redundant HVAC systems, whole building and biorepository security systems and a temperature monitoring system for all freezers and refrigerators with a 21 CFR Part 11 compliant audit trail.
'There are many biorepositories, but LabConnect’s facility is truly state-of-the art, using the most advanced technology available to provide the best protection in the industry for biospecimens,' said George Lewis, Senior Engineering Technician at Johnson Controls, which supplies equipment to the facility.
LabConnect is able to track sample locations and consolidate data within a centralised database accessible to researchers 24/7 using its SampleGISTICS system.